Literature DB >> 33731816

Human breast milk-derived exosomes may help maintain intestinal epithelial barrier integrity.

Shan He1,2, Gang Liu1,3, Xueping Zhu4.   

Abstract

BACKGROUND: This study explores the functions of exosomes derived from human breast milk (HBM) in vivo and in vitro.
METHODS: HBM-derived exosomes were collected from healthy lactating mothers. In vitro analysis were divided into five groups: (1) a control with no added agents, (2) exosomes added, (3) stimulated with lipopolysaccharide (LPS), (4) pretreated with exosomes and stimulated with LPS, and (5) pretreated with exosome-free HBM and stimulated with LPS. For in vivo analysis, mouse pups were randomly assigned to four groups: (1) a control group of breastfed pups, (2) necrotizing enterocolitis-induced (NEC) pups, (3) pups pretreated with HBM-derived exosomes 6 h before being induced by NEC, and (4) pups pretreated with exosome-free HBM 6 h before NEC induction.
RESULTS: Expression of zonula occludens-1 (ZO-1), claudin-1, and occludin were decreased in groups 3 and 5. In the animal model, mice pups in group 3 showed milder intestinal tissue injury than those in group 2 or 4 and had lower levels of the proinflammatory cytokines and higher levels of epithelial tight-junction proteins than groups 2 and 4.
CONCLUSIONS: HBM-derived exosomes exert beneficial effects in preventing NEC by reducing inflammation and injury to the intestinal epithelium as well as by restoring intestinal tight-junction proteins. IMPACT: HBM-derived exosomes can help protect the epithelial tight-junction proteins ZO-1, claudin, and occludin from inflammatory attack. This study sought (1) to analyze whether there were differences in exosome levels between the human breast milk (HBM) of mothers who had delivered preterm or at term and (2) to investigate whether these exosomes could help sustain the intestinal epithelial tight-junction proteins ZO-1, claudin-1, and occludin in the presence of NEC in vitro and in vivo.
© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33731816     DOI: 10.1038/s41390-021-01449-y

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  1 in total

1.  A guide to histomorphological evaluation of intestinal inflammation in mouse models.

Authors:  Ulrike Erben; Christoph Loddenkemper; Katja Doerfel; Simone Spieckermann; Dirk Haller; Markus M Heimesaat; Martin Zeitz; Britta Siegmund; Anja A Kühl
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15
  1 in total
  6 in total

Review 1.  Recent Advances on the Function and Purification of Milk Exosomes: A Review.

Authors:  Xiaoping Li; Lan Su; Xinling Zhang; Qi Chen; Ying Wang; Zhenwei Shen; Tian Zhong; Ling Wang; Ying Xiao; Xiao Feng; Xi Yu
Journal:  Front Nutr       Date:  2022-06-09

2.  Intestinal Epithelial Barrier Function and Necrotizing Enterocolitis.

Authors:  Elizabeth Managlia; Xiaocai Yan; Isabelle G De Plaen
Journal:  Newborn (Clarksville)       Date:  2022-03-31

3.  Effects of Proteins and Mineral Ions on the Physicochemical Properties of 1,3-Dioleoyl-2-Palmitoylglycerol Emulsion to Mimic a Liquid Infant Formula.

Authors:  Qi Wang; Yuxi Xu; Yanchen Liu; Fang Qian; Guangqing Mu; Xuemei Zhu
Journal:  Front Nutr       Date:  2022-06-13

4.  A systematic review on the modifications of extracellular vesicles: a revolutionized tool of nano-biotechnology.

Authors:  Alok Raghav; Goo-Bo Jeong
Journal:  J Nanobiotechnology       Date:  2021-12-30       Impact factor: 10.435

Review 5.  Beneficial Effects of Bovine Milk Exosomes in Metabolic Interorgan Cross-Talk.

Authors:  Jorge García-Martínez; Íñigo M Pérez-Castillo; Rafael Salto; José M López-Pedrosa; Ricardo Rueda; María D Girón
Journal:  Nutrients       Date:  2022-03-30       Impact factor: 5.717

Review 6.  The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer.

Authors:  Yueyuan Zhou; Zhongdang Xiao; Wei Zhu
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.